AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8487046
Drug: 12 g/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g/m2 MTX as a 4‐hour infusion (high-dose [HDM])
Trial: 8487046
Drug: 1 g/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/m2 as a 36‐hour infusion (intermediate-dose [IDM])
Trial: 3320181
Drug: Insulin 10
RxNorm normalized name: Human regular insulin 100 unit/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 10 U and glucagon 1 mg in 500 ml 5% glucose in water via a peripheral vein for 2-6 h three times every day for 3 weeks
Trial: 25360840
Drug: Xinxuekang (XXK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinxuekang (XXK) capsules
Trial: 25360840
Drug: Compound Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Danshen (CDS) tablets
Trial: 22104015
Drug: Everolimus and
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus and octreotide combination therapy for 12 months
Trial: 16234004
Drug: Octreotide monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide monotherapy
Trial: 16534006
Drug: Acetaminophen (frequent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (frequent use > or =22 d/mo)
Trial: 16534006
Drug: NSAIDs (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (high dose > or =15 tablets per week)
Trial: 16534006
Drug: Acetaminophen (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (high dose > or =15 tablets per week)
Trial: 11569654
Drug: Cotrimoxazole (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (single dose)
Trial: 8482993
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg methylprednisolone acetate injected locally
Trial: 3616850
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of erythromycin daily for a week
Trial: 3616850
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of erythromycin daily for a week
Trial: 22703532
Drug: Fludrocortisone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone 50 μg orally
Trial: 22703532
Drug: Hydrocortisone 50
RxNorm normalized name: hydrocortisone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 50 mg intravenously
Trial: 18094720
Drug: High-dose lipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lipid formulation of amphotericin B (HD‐LPD/AMB)
Trial: 11027806
Drug: Combined hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hepatitis A and B vaccine (HAB)
Trial: 11027806
Drug: Concomitant hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant hepatitis A and B vaccines (HAV + HBV)
Trial: 1610421
Drug: Domiodol 60
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Domiodol 60 mg t.i.d.
Trial: 6369431
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine intrathecally (spinal group)
Trial: 6369431
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg body weight of morphine i.v. (i.V. group)
Trial: 6369431
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg body weight epidurally (PDA group)
Trial: 6369431
Drug: CSF morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSF morphine concentration 24 hrs after injection
Trial: 30995657
Drug: HCO3 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCO3 (oral sodium bicarbonate)
Trial: 30291483
Drug: 400-μg misoprostol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400-μg misoprostol rectally with 5-IU oxytocin IV
Trial: 30291483
Drug: 400-μg misoprostol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400-μg misoprostol sublingually with 5-IU oxytocin IV
Trial: 30291483
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between sublingual and rectal misoprostol
Trial: 25800768
Drug: Early palliative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early palliative care (PC) consultation, structured PC telehealth nurse coaching sessions (once per week for six sessions), and monthly follow-up
Trial: 25800768
Drug: Delayed palliative
RxNorm normalized name: Various pain palliation radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed palliative care (PC) consultation, structured PC telehealth nurse coaching sessions (once per week for six sessions), and monthly follow-up
Trial: 31774584
Drug: Lorcaserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin (20 mg)
Trial: 21412231
Drug: Lorcaserin (supratherapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin (supratherapeutic doses)
Trial: 21412231
Drug: Lorcaserin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin (all doses)
Trial: 27253658
Drug: Zolpidem (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (15 and 30 mg)
Trial: 19536092
Drug: Oxaliplatin and
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin and capecitabine treatment
Trial: 9580448
Drug: Metamizol 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizol 2 g
Trial: 1778353
Drug: Active policy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active policy with either insulin or sulphonylurea aiming to reduce fasting plasma glucose to under 6 mmol/l
Trial: 1778353
Drug: Tight control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight control aiming for less than 150/85 mm Hg with either an angiotensin‐converting enzyme inhibitor or a Beta‐blocker
Trial: 31927343
Drug: Observational cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational cohort (OC) receiving oral standard of care
Trial: 29228795
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A eye ointment (VAEO) administered every 6 hr for 5 days
Trial: 26404953
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.5 μg calcitriol, 75 mg acetylsalicylic acid, and 1250 mg calcium carbonate (n = 209)
Trial: 22537957
Drug: Ulinastatin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin treatment (1.0×10(4) U/kg)
Trial: 19995589
Drug: Ethanol dehydration
RxNorm normalized name: Dehydrated ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol dehydration with 15s for each solution (Group 2)
Trial: 18585508
Drug: Abciximab bolus
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab bolus + infusion (0.125 microg/[kg min] for 12 hours)
Trial: 12121427
Drug: One daily
RxNorm normalized name: One Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One daily bout of walking (Group S1)
Trial: 12121427
Drug: Two daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two daily bouts of walking (Group S2)
Trial: 10080677
Drug: Enteral Nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral Nutrition (EN) - 37 kcal/kg/day + 2.0 g proteins/kg/day for 34 days
Trial: 10080677
Drug: Standard Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Oral Diet (SD)
Trial: 2833577
Drug: Chemotherapy (VP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (VP and CAP combined)
Trial: 24962635
Drug: Gemigliptin 50
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemigliptin 50 mg once daily for 6 days + Glimepiride 4 mg on day 7
Trial: 24962635
Drug: Glimepiride 4
RxNorm normalized name: glimepiride 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 4 mg single dose
Trial: 20524875
Drug: Glutathione, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione, 500 mg/day for 4 weeks
Trial: 15824216
Drug: Verteporfin infusion
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin infusion with reduced fluence (RF) rate (300 mW/cm² for 83 seconds, light dose of 25 J/cm²)
Trial: 15824216
Drug: Verteporfin infusion
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin infusion with standard fluence (SF) rate (600 mW/cm² for 83 seconds, light dose of 50 J/cm²)
Trial: 12913718
Drug: Primary plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary plus booster immunizations (6 vaccine doses)
Trial: 12913718
Drug: Primary immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary immunization (3 doses of vaccine)
Trial: 8923161
Drug: Dexfenfluramine (dF)
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine (dF) 15 mg bd
Trial: 25340832
Drug: Retapamulin 1%
RxNorm normalized name: RETAPAMULIN 1% OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retapamulin 1% ointment
Trial: 22759797
Drug: Inhaled treprostinil
RxNorm normalized name: treprostinil Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled treprostinil (upper quartile of NT-proBNP)
Trial: 20082236
Drug: LEF-anti-TNF-alpha combination
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEF-anti-TNF-alpha combination therapy
Trial: 20082236
Drug: MTX-anti-TNF-alpha combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX-anti-TNF-alpha combination therapy
Trial: 17587447
Drug: Chemotherapy (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (specific chemotherapy not detailed)
Trial: 8521431
Drug: Acidulated phosphate
RxNorm normalized name: Acidulated Phosphate Fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidulated phosphate fluoride (APF) gel
Trial: 31148344
Drug: Pharmacists' beliefs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists' beliefs about synthetic drugs
Trial: 31148344
Drug: Pharmacists' beliefs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists' beliefs about natural drugs
Trial: 31148344
Drug: Pharmacists' opinions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists' opinions on reporting adverse reactions of natural drugs
Trial: 26536871
Drug: Paclitaxel (PTX)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (PTX) alone (80 mg/m², d1; n=47)
Trial: 26536871
Drug: Iniparib plus
RxNorm normalized name: Iniparib
DrugBank: Iniparib (DB13877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iniparib plus weekly Paclitaxel (PWI) (11.2 mg/kg, d1; n=46)
Trial: 26536871
Drug: Iniparib plus
RxNorm normalized name: Iniparib
DrugBank: Iniparib (DB13877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iniparib plus twice-weekly Paclitaxel (PTI) (5.6 mg/kg, d1, 4; n=48)
Trial: 24400341
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training & Alagebrium (200 mg/day)
Trial: 24400341
Drug: No exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No exercise training & Alagebrium (200 mg/day)
Trial: 16984235
Drug: rhIGF‐I/IGFBP‐3 complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I/IGFBP‐3 complex (SomatoKine) 0.4 mg/kg/day
Trial: 15533733
Drug: Nifedipine coat-core
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine coat-core (20 mg once daily)
Trial: 11579649
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rifampicin 600 mg plus ofloxacin 400 mg plus minocycline 100 mg (ROM) administered as single dose
Trial: 8300461
Drug: Salbutamol inhaler
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol inhaler (100 mcg) 2 puffs tds
Trial: 3572629
Drug: Formula B
RxNorm normalized name: Formula B
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula B (3.6 g/kg/d protein, 115 kcal/kg/d energy)
Trial: 3572629
Drug: Formula C
RxNorm normalized name: Stress Formula Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula C (3.5 g/kg/d protein, 149 kcal/kg/d energy)
Trial: 3572629
Drug: Formula A
RxNorm normalized name: ACD-Solution Formula A
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formula A (2.24 g/kg/d protein, 113 kcal/kg/d energy)
Trial: 24705232
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (0.2 mg) administered 2 hours before anesthesia
Trial: 22760531
Drug: Delayed antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antimicrobial treatment with amoxicillin‐clavulanate for 7 days
Trial: 22760531
Drug: Immediate antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antimicrobial treatment with amoxicillin‐clavulanate for 7 days
Trial: 22760531
Drug: Delayed antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antimicrobial treatment
Trial: 10625579
Drug: Topical analgesia
RxNorm normalized name: ANALGESIC TOP GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical analgesia cream (EMLA)
Trial: 10625579
Drug: Cooling (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling (all treatments)
Trial: 10625579
Drug: Pin-pricking (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pin-pricking (all treatments)
Trial: 1536784
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with traditional Chinese medicinal plants for 8 weeks
Trial: 6492228
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (10 g) with acetaminophen (1 g)
Trial: 6492228
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (10 g) with sodium sulfate (18 g) and acetaminophen (1 g)
Trial: 6492228
Drug: Sodium sulfate
RxNorm normalized name: Sodium Sulfate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium sulfate (18 g) with acetaminophen (1 g)
Trial: 6492228
Drug: Acetaminophen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1 g) alone
Trial: 19262392
Drug: Scalp block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp block with 20 ml 0.5% bupivacaine
Trial: 11915634
Drug: New injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New injection system
Trial: 9765767
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (160 mg 3 times daily for 10 days)
Trial: 3057329
Drug: Bay 1099
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bay 1099 (25, 50, or 100 mg)
Trial: 3057329
Drug: Bay 1099
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bay 1099 (50 mg tid)
Trial: 28249150
Drug: Nemolizumab 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab 0.1 mg/kg every 4 weeks
Trial: 28249150
Drug: Nemolizumab 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab 0.5 mg/kg every 4 weeks
Trial: 28249150
Drug: Nemolizumab 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab 2.0 mg/kg every 4 weeks
Trial: 23567902
Drug: WISE intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WISE intervention (motivational interviewing and cognitive behavioral therapy)
Trial: 12040433
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with NA
Trial: 2568643
Drug: procyclidine 5
RxNorm normalized name: procyclidine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: procyclidine 5 mg t.i.d.
Trial: 2568643
Drug: promethazine 25
RxNorm normalized name: promethazine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine 25 mg t.i.d.
Trial: 2568643
Drug: haloperidol 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol 4.5 mg t.i.d. (group HPL)
Trial: 27899529
Drug: rTFA (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTFA (2% of daily energy intake from ruminant TFA)
Trial: 27899529
Drug: iTFA (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iTFA (2% of daily energy intake from industrial TFA)
Trial: 22214714
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg, thrice a day) for 4 weeks
Trial: 19368965
Drug: Budesonide/formoterol 200/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 200/6 microg twice daily plus as-needed
Trial: 19368965
Drug: Budesonide/formoterol 800/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 800/12 microg twice daily
Trial: 16716321
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of prednisone (20 mg/d), aspirin (100 mg/d), folate (5 mg every second day), and progesterone (20 mg/d) for the first 12 weeks of gestation.
Trial: 16716321
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of prednisone, aspirin, folate, and progesterone.
Trial: 9134638
Drug: Anti-factor VIII
RxNorm normalized name: Anti-factor VIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-factor VIII inhibitors (a-fVIII)
Trial: 9134638
Drug: Lupus anticoagulants
RxNorm normalized name: Canis lupus familiaris skin
DrugBank: Canis lupus familiaris skin (DB10409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupus anticoagulants (LAs)
Trial: 7934158
Drug: rhGM‐CSF with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM‐CSF with standard induction chemotherapy (TAD)
Trial: 2849968
Drug: Pipecuronium 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipecuronium 0.07 mg kg‐1
Trial: 29194612
Drug: Nanocurcumin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocurcumin therapy for 6 months
Trial: 29194612
Drug: Nanocurcumin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocurcumin therapy
Trial: 28753849
Drug: ODM-201 (200-1800mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODM-201 (200-1800mg, oral, twice daily)
Trial: 25887096
Drug: Extended-release mixed
RxNorm normalized name: Amphetamine Mixed Salts Extended-Release Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release mixed amphetamine salts (60 mg)
Trial: 25887096
Drug: Extended-release mixed
RxNorm normalized name: Amphetamine Mixed Salts Extended-Release Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release mixed amphetamine salts (80 mg)
Trial: 17175661
Drug: Zemaira (study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zemaira (study drug)
Trial: 17175661
Drug: Prolastin (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolastin (control drug)
Trial: 12547873
Drug: HIM2 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIM2 (1.0 mg/kg)
Trial: 12547873
Drug: HIM2 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIM2 (0.5 and 1.0 mg/kg)
Trial: 8938913
Drug: Clozapine 200
RxNorm normalized name: clozapine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 200 mg/day (withdrawn abruptly)
Trial: 1411636
Drug: 60 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 single oral dose on day 8
Trial: 1411636
Drug: 60 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 and 120 mg/m2 single oral doses on days 8 and 15
Trial: 1411636
Drug: 120 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/m2 and 240 mg/m2 single oral doses on days 8 and 15
Trial: 1411636
Drug: 60 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 single oral doses on 5 consecutive days from days 8 to 12
Trial: 1411636
Drug: 50 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 three times a day at 6-hour intervals on day 8
Trial: 1411636
Drug: 240 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg/m2 single oral dose
Trial: 1411636
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses on 1 day or 5 consecutive days
Trial: 30571332
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (eicosapentaenoic acid+docosahexaenoic acid; 8‐10 g for 2‐5 days preoperatively, and then 2 g/d postoperatively)
Trial: 22574800
Drug: Behaviour Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour Therapy + Constructive Worry (BT + CW)